Precision diagnostics in transplantation: From bench to bedside

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 562-568

  Mengel, M ^a,b   Campbell, P ^a,b   Gebel, H ^a,c   Randhawa, P ^a,d   Rodriguez, E R ^a,e   Colvin, R ^f   Conway, J ^g   Hachem, R ^h   Halloran, P F ^b   Keshavjee, S ^g   Nickerson, P ⁱ   Murphey, C ^j   O'Leary, J ^k   Reeve, J ^b   Tinckam, K ^g   Reed, E F ^a,l  

^a American Society of Transplantation   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j Southwest Immunodiagnostics Inc   (United States)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Antibody testing; Banff; precision diagnostics; transplantation

Indexed keywords

ANTIBODY; DONOS SPECIFIC HLA ANTIBODY; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; BLOOD GROUP ABO INCOMPATIBILITY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; INNATE IMMUNITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; T CELL MEDIATED REJECTION; TRANSPLANTATION;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREDICTIVE VALUE OF TESTS; SOCIETIES, MEDICAL; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION;

EID: 84874444909     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04344.x     Document Type: Conference Paper

References (66)

1. Mengel M, Husain S, Hidalgo L, Sis B,. Phenotypes of antibody-mediated rejection in organ transplants. Transpl Int 2012; 25: 611-622.
2. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting Report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
3. Bray RA, Nickerson PW, Kerman RH, Gebel HM,. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41-54.
4. Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805-810.
5. Gebel HM, Moussa O, Eckels DD, Bray RA,. Donor-reactive HLA antibodies in renal allograft recipients: Considerations, complications, and conundrums. Hum Immunol 2009; 70: 610-617.
6. Liu JP, Lin JR, Chow SC,. Inference on treatment effects for targeted clinical trials under enrichment design. Pharm Stat 2009; 8: 356-370.
7. Mirnezami R, Nicholson J, Darzi A,. Preparing for precision medicine. N Engl J Med 2012; 366: 489-491.
8. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6: 2307-2315.
9. Gebel HM, Bray RA, Nickerson P,. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500.
10. Cook DJ, Terasaki PI, Iwaki Y, et al. The flow cytometry crossmatch in kidney transplantation. Clin Transplant 1987; 409-414.
11. Thistlethwaite JR, Jr., Buckingham M, Stuart JK, Gaber AO, Mayes JT, Stuart FP,. T cell immunofluorescence flow cytometry cross-match results in cadaver donor renal transplantation. Transplant Proc 1987; 19 (1 Pt 1): 722-724.
12. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
13. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
14. Amico P, Hirt-Minkowski P, Honger G, et al. Risk stratification by the virtual crossmatch: A prospective study in 233 renal transplantations. Transpl Int 2011; 24: 560-569.
15. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
16. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB,. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12-17.
17. Honger G, Wahrmann M, Amico P, Hopfer H, Bohmig GA, Schaub S,. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplant 2010; 89: 1471-1475.
18. Chen G, Sequeira F, Tyan DB,. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849-858.
19. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056.
20. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (1 Pt 1): 396-399.
21. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transplant 2011; 17: 357-368.
22. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
23. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
24. Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23: 1135-1141.
25. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5: 131-138.
26. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998; 116: 812-820.
27. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplant 1998; 65: 648-653.
28. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973-980.
29. Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: Targets of antibody-mediated rejection in heart transplantation. Transplant 2011; 91: 1153-1158.
30. Dinavahi R, George A, Tretin A, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol 2011; 22: 1168-1178.
31. Hachem RR, Tiriveedhi V, Patterson GA, Aloush A, Trulock EP, Mohanakumar T,. Antibodies to K-alpha 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant 2012; 12: 2164-2171.
32. Sigdel TK, Li L, Tran TQ, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012; 23: 750-763.
33. Ziegler ME, Souda P, Jin YP, Whitelegge JP, Reed EF,. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One 2012; 7: e29472.
34. Rydberg L,. ABO-incompatibility in solid organ transplantation. Transfus Med 2001; 11: 325-342.
35. AuBuchon JP, de Wildt-Eggen J, Dumont LJ,. Reducing the variation in performance of antibody titrations. Arch Pathol Lab Med 2008; 132: 1194-1201.
36. Lindberg L, Johansson SM, Liu J, Grufman P, Holgersson J,. Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B? Transfusion 2011; 51: 494-503.
37. Ferrari P, Fidler S, Wright J, et al. Virtual crossmatch approach to maximize matching in paired kidney donation. Am J Transplant 2011; 11: 272-278.
38. Gentry SE, Montgomery RA, Segev DL,. Controversies in kidney paired donation. Adv Chronic Kidney Dis 2012; 19: 257-261.
39. Solez K,. History of the Banff classification of allograft pathology as it approaches its 20th year. Curr Opin Organ Transplant 2010; 15: 49-51.
40. Mengel M, Sis B, Halloran PF,. SWOT analysis of Banff: Strengths, weaknesses, opportunities, and threats of the International Banff consensus process and classification system for renal allograft pathology. Am J Transplant 2007; 7: 2221-2226.
41. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
42. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
43. Sis B, Mengel M, Haas M, et al. Banff '09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups. Am J Transplant 2010; 10: 464-471.
44. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
45. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56-65.
46. Hirohashi T, Uehara S, Chase CM, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010; 10: 510-517.
47. Dean PG, Park WD, Cornell LD, Gloor JM, Stegall MD,. Intragraft gene expression in positive crossmatch kidney allografts: Ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012; 12: 1551-1563.
48. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
49. Sis B, Jhangri G, Bunnag S, Allanach K, Kaplan B, Halloran PF,. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
50. Atencio IA, Shadan FF, Zhou XJ, Vaziri ND, Villarreal LP,. Adult mouse kidneys become permissive to acute polyomavirus infection and reactivate persistent infections in response to cellular damage and regeneration. J Virol 1993; 67: 1424-1432.
51. Fonseca LE, Jr., Shapiro R, Randhawa PS,. Occurrence of urinary tract infection in patients with renal allograft biopsies showing neutrophilic tubulitis. Mod Pathol 2003; 16: 281-285.
52. Baid-Agrawal S, Farris AB, III, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879-885.
53. Kashyap R, Shapiro R, Jordan M, Randhawa PS,. The clinical significance of cytomegaloviral inclusions in the allograft kidney. Transplant 1999; 67: 98-103.
54. Randhawa PS, Magnone M, Jordan M, Shapiro R, Demetris AJ, Nalesnik M,. Renal allograft involvement by Epstein-Barr virus associated post-transplant lymphoproliferative disease. Am J Surg Pathol 1996; 20: 563-571.
55. Dupuy A, Simon RM,. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007; 99: 147-157.
56. Allison DB, Cui X, Page GP, Sabripour M,. Microarray data analysis: From disarray to consolidation and consensus. Nat Rev Genet 2006; 7: 55-65.
57. Crawford SL,. Correlation and regression. Circulation 2006; 114: 2083-2088.
58. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-138.
59. Subramanian J, Simon R,. An evaluation of resampling methods for assessment of survival risk prediction in high-dimensional settings. Stat Med 2011; 30: 642-653.
60. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM,. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005; 51: 1335-1341.
61. Kaneda H, Waddell TK, de Perrot M, et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6: 544-551.
62. Kang CH, Anraku M, Cypel M, et al. Transcriptional signatures in donor lungs from donation after cardiac death vs after brain death: A functional pathway analysis. J Heart Lung Transplant 2011; 30: 289-298.
63. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1: 4ra9.
64. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431-1440.
65. Famulski KS, de Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in human kidney transplants. JASN 2012; 23: 948-958.
66. Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120: 1862-1872.